Healthcare

Shockwave makes circulatory restoration products for calcified coronary and peripheral artery disease. Johnson & Johnson's fiscal 2025 Form 10-K places it in the MedTech cardiovascular portfolio.

• Controlling stakeJohnson & Johnson

Signifeye is an eye-hospital name EssilorLuxottica includes with its European clinics in the 2025 universal registration document.

• Controlling stakeEssilorLuxottica

SIMPONI is a treatment for rheumatoid arthritis and other inflammatory diseases, also sold as SIMPONI ARIA. Johnson & Johnson's fiscal 2025 Form 10-K lists both as key Innovative Medicine products.

• Controlling stakeJohnson & Johnson

SPRAVATO is an esketamine nasal spray used with an oral antidepressant for treatment-resistant depression. Johnson & Johnson's fiscal 2025 Form 10-K lists it as a key Innovative Medicine product.

• Controlling stakeJohnson & Johnson

STELARA is a treatment for psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis. Johnson & Johnson's fiscal 2025 Form 10-K lists it as a key product and says biosimilar competition was reducing sales.

• Controlling stakeJohnson & Johnson

SYMTUZA is a once-daily single-tablet regimen for HIV. Johnson & Johnson's fiscal 2025 Form 10-K lists it as a key Innovative Medicine product.

• Controlling stakeJohnson & Johnson

TALVEY is a bispecific antibody for relapsed or refractory multiple myeloma. Johnson & Johnson's fiscal 2025 Form 10-K lists it as a key Innovative Medicine product.

• Controlling stakeJohnson & Johnson

TECNIS is a brand of intraocular lenses for cataract surgery. Johnson & Johnson's fiscal 2025 Form 10-K lists TECNIS in the MedTech Vision portfolio.

• Controlling stakeJohnson & Johnson

TECVAYLI is a bispecific antibody for relapsed or refractory multiple myeloma. Johnson & Johnson's fiscal 2025 Form 10-K lists it as a key Innovative Medicine product.

• Controlling stakeJohnson & Johnson

TREMFYA is a treatment for psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis. Johnson & Johnson's fiscal 2025 Form 10-K lists it as a key Innovative Medicine product.

• Controlling stakeJohnson & Johnson

UPTRAVI is an oral and intravenous treatment for pulmonary arterial hypertension. Johnson & Johnson's fiscal 2025 Form 10-K lists it as a key Innovative Medicine product.

• Controlling stakeJohnson & Johnson

A personal-health brand in Procter & Gamble's Health Care segment. The 10-K groups it with respiratory treatments.

• Controlling stakeProcter & Gamble

VillageMD includes Village Medical, Summit Health, and CityMD. The acquisition release describes a contingent right tied to a future sale of these interests.

• Portfolio investmentSycamore Partners

XARELTO is an oral anticoagulant. Johnson & Johnson's fiscal 2025 Form 10-K lists it as a key Innovative Medicine product and says it was co-developed with Bayer HealthCare AG.

• Controlling stakeJohnson & Johnson

ZYTIGA is a treatment for prostate cancer. Johnson & Johnson's fiscal 2025 Form 10-K lists it as a key Innovative Medicine product and notes loss of exclusivity in the 2025 sales discussion.

• Controlling stakeJohnson & Johnson